Skip to main content

Research Repository

Advanced Search

ELF5 drives lung metastasis in luminal breast cancer through recruitment of Gr1+ CD11b+ myeloid-derived suppressor cells (2015)
Journal Article
Gallego-Ortega, D., Ledger, A., Roden, D. L., Law, A. M., Magenau, A., Kikhtyak, Z., Cho, C., Allerdice, S. L., Lee, H. J., Valdes-Mora, F., Herrmann, D., Salomon, R., Young, A. I., Lee, B. Y., Marcelo Sergio, C., Kaplan, W., Piggin, C., Conway, J. R., Rabinovich, B., Millar, E. K., …Ormandy, C. J. (2015). ELF5 drives lung metastasis in luminal breast cancer through recruitment of Gr1+ CD11b+ myeloid-derived suppressor cells. PLoS Biology, 13(12), Article e1002330. https://doi.org/10.1371/journal.pbio.1002330

During pregnancy, the ETS transcription factor ELF5 establishes the milk-secreting alveolar cell lineage by driving a cell fate decision of the mammary luminal progenitor cell. In breast cancer, ELF5 is a key transcriptional determinant of tumor subt... Read More about ELF5 drives lung metastasis in luminal breast cancer through recruitment of Gr1+ CD11b+ myeloid-derived suppressor cells.

Clinical utility of reverse phase protein array for molecular classification of breast cancer (2015)
Journal Article
Negm, O. H., Muftah, A. A., Aleskandarany, M. A., Hamed, M. R., Ahmad, D. A., Nolan, C. C., Diez-Rodriguez, M., Tighe, P. J., Ellis, I. O., Rakha, E. A., & Green, A. R. (2016). Clinical utility of reverse phase protein array for molecular classification of breast cancer. Breast Cancer Research and Treatment, 155(1), 25-35. https://doi.org/10.1007/s10549-015-3654-2

Reverse Phase Protein Array (RPPA) represents a sensitive and high-throughput technique allowing simultaneous quantitation of protein expression levels in biological samples. This study aimed to confirm the ability of RPPA to classify archival formal... Read More about Clinical utility of reverse phase protein array for molecular classification of breast cancer.

Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer (2015)
Journal Article
Alsubhi, N., Middleton, F., Abdel-Fatah, T. M., Stephens, P., Doherty, R., Arora, A., Moseley, P. M., Chan, S. Y., Aleskandarany, M. A., Green, A. R., Rakha, E. A., Ellis, I. O., MARTIN, S., Curtin, N. J., & Madhusudan, S. (2016). Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer. Molecular Oncology, 10(2), 213-223. https://doi.org/10.1016/j.molonc.2015.09.009

Radiation‐induced DNA damage activates the DNA damage response (DDR). DDR up‐regulation may predict radio‐resistance and increase the risk of early local recurrence despite radiotherapy in early stage breast cancers. In 1755 early stage breast cancer... Read More about Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer.

PKC? attenuates jagged-1-mediated notch signaling in ErbB-2-positive breast cancer to reverse trastuzumab resistance (2015)
Journal Article
Pandya, K., Wyatt, D., Gallagher, B., Shah, D., Baker, A., Bloodworth, J., Zlobin, A., Pannuti, A., Green, A., Ellis, I. O., Filipovic, A., Sagert, J., Rana, A., Albain, K. S., Miele, L., Denning, M. F., & Osipo, C. (2016). PKCα attenuates jagged-1-mediated notch signaling in ErbB-2-positive breast cancer to reverse trastuzumab resistance. Clinical Cancer Research, 22(1), 175-186. https://doi.org/10.1158/1078-0432.CCR-15-0179

Purpose: Breast cancer is the second leading cause of cancer mortality among women worldwide. The major problem with current treatments is tumor resistance, recurrence, and disease progression. ErbB-2–positive breast tumors are aggressive and frequen... Read More about PKC? attenuates jagged-1-mediated notch signaling in ErbB-2-positive breast cancer to reverse trastuzumab resistance.

Construction of tissue microarrays from core needle biopsies: a systematic literature review (2015)
Journal Article
Albanghali, M., Green, A., Rakha, E., Aleskandarany, M., Nolan, C., Ellis, I., & Cheung, K.-L. (2016). Construction of tissue microarrays from core needle biopsies: a systematic literature review. Histopathology, 68(3), 323-332. https://doi.org/10.1111/his.12802

In some clinical circumstances, core needle biopsy (CNB) may be the only source of material from cancer tissue for diagnostic use. The volume of tissue available in a CNB is low, and opportunities for research use can therefore be limited. The tissue... Read More about Construction of tissue microarrays from core needle biopsies: a systematic literature review.

HAGE in triple-negative breast cancer is a novel prognostic, predictive, and actionable biomarker: a transcriptomic and protein expression analysis (2015)
Journal Article
Abdel-Fatah, T. M., McArdle, S. E., Agarwal, D., Moseley, P. M., Green, A. R., Ball, G. R., Graham Pockley, A., Ellis, I. O., Rees, R. C., & Chan, S. Y. (2015). HAGE in triple-negative breast cancer is a novel prognostic, predictive, and actionable biomarker: a transcriptomic and protein expression analysis. Clinical Cancer Research, 22(4), 905-914. https://doi.org/10.1158/1078-0432.CCR-15-0610

The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer (2015)
Journal Article
Magnani, L., Patten, D. K., Nguyen, V. T. M., Hong, S.-P., Steel, J. H., Patel, N., Lombardo, Y., Faronato, M., Gomes, A. R., Woodley, L., Page, K., Guttery, D., Primrose, L., Garcia, D. F., Shaw, J., Viola, P., Green, A., Nolan, C., Ellis, I. O., Rakha, E. A., …Coombes, C. R. (2015). The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer. Oncotarget, 6(26), 21878-21891. https://doi.org/10.18632/oncotarget.4243

Over 30% of ERα breast cancer patients develop relapses and progress to metastatic disease despite treatment with endocrine therapies. The pioneer factor PBX1 translates epigenetic cues and mediates estrogen induced ERα binding. Here we demonstrate t... Read More about The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer.

The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways (2015)
Journal Article
Jerjees, D. A., Negm, O. H., Alabdullah, M. L., Mirza, S., Alkaabi, M., Hameed, M. R., Abduljabbar, R., Muftah, A., Nolan, C. C., Green, A. R., Tighe, P. J., Band, V., Ellis, I. O., & Rakha, E. A. (2015). The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways. Breast Cancer Research and Treatment, 150(1), 91-103. https://doi.org/10.1007/s10549-015-3308-4

The mammalian target of rapamycin complex 1 (mTORC1) is a downstream of the PI3K/Akt pathway which affects cancer development. mTORC1 has many downstream signalling effectors that can enhance different cellular responses. This study aims to investiga... Read More about The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways.

DNA damage response markers are differentially expressed in BRCA-mutated breast cancers (2015)
Journal Article
Aleskandarany, M., Caracappa, D., Nolan, C. C., Macmillan, R. D., Ellis, I. O., Rakha, E. A., & Green, A. R. (2015). DNA damage response markers are differentially expressed in BRCA-mutated breast cancers. Breast Cancer Research and Treatment, 150(1), 81-90. https://doi.org/10.1007/s10549-015-3306-6

Cells have stringent DNA repair pathways that are specific for each different set of DNA lesions which is accomplished through the integration of complex array of proteins. However, BRCA-mutated breast cancer (BC) has defective DNA repair mechanisms.... Read More about DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.

Transcriptomic and protein expression analysis reveals clinicopathological significance of bloom syndrome helicase (BLM) in breast cancer (2015)
Journal Article
Arora, A., Abdel-Fatah, T., Agarwal, D., Doherty, R., Moseley, P. M., Aleskandarany, M. A., Green, A. R., Ball, G., Alshareeda, A., Rakha, E., Chan, S. Y., Ellis, I. O., & Madhusudan, S. (2015). Transcriptomic and protein expression analysis reveals clinicopathological significance of bloom syndrome helicase (BLM) in breast cancer. Molecular Cancer Therapeutics, 14(4), https://doi.org/10.1158/1535-7163.MCT-14-0939

Bloom syndrome helicase (BLM) has key roles in homologous recombination repair, telomere maintenance, and DNA replication. Germ-line mutations in the BLM gene causes Bloom syndrome, a rare disorder characterized by premature aging and predisposition... Read More about Transcriptomic and protein expression analysis reveals clinicopathological significance of bloom syndrome helicase (BLM) in breast cancer.